KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Vertex Pharmaceuticals (VRTX) over the last 15 years, with Q4 2025 value amounting to $30.5 million.

  • Vertex Pharmaceuticals' Deferred Taxes fell 4089.15% to $30.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$510.8 million, marking a year-over-year decrease of 4644.5%. This contributed to the annual value of -$510.8 million for FY2025, which is 4644.5% down from last year.
  • Vertex Pharmaceuticals' Deferred Taxes amounted to $30.5 million in Q4 2025, which was down 4089.15% from -$235.9 million recorded in Q3 2025.
  • Vertex Pharmaceuticals' Deferred Taxes' 5-year high stood at $148.1 million during Q4 2022, with a 5-year trough of -$237.9 million in Q2 2021.
  • In the last 5 years, Vertex Pharmaceuticals' Deferred Taxes had a median value of -$117.2 million in 2023 and averaged -$91.3 million.
  • In the last 5 years, Vertex Pharmaceuticals' Deferred Taxes surged by 45346.06% in 2022 and then crashed by 82195.12% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Deferred Taxes (Quarter) stood at -$41.9 million in 2021, then skyrocketed by 453.46% to $148.1 million in 2022, then crashed by 188.45% to -$131.0 million in 2023, then skyrocketed by 139.39% to $51.6 million in 2024, then crashed by 40.89% to $30.5 million in 2025.
  • Its last three reported values are $30.5 million in Q4 2025, -$235.9 million for Q3 2025, and -$113.8 million during Q2 2025.